This journal recently reported a survey of statistical quality control (SQC) practices in a group of academic medical centers. 1 The 21 laboratories represented "highly regarded academic institutions comprising the entirety of the US News & World Report 2016 to 2017 honor roll list." 1 The laboratories utilized a wide variety of instrument systems for routine chemistry and immunochemistry testing, thus their SQC practices should be representative of the best practices in US laboratories today.
The report describes a wide variation of practices from laboratory to laboratory for the frequency of SQC events, but surprisingly common usage of 2 standard deviation (SD) control limits in most of the laboratories. We say surprising because 2 SD control limits are known to cause a high false rejection rate, for example 5% for a single control measurement or level, 9% for two control measurements or levels, and 14% for three control measurements or levels. Those false rejections propagate similarly across laboratory tests; for example, if a single control is measured on three simultaneous tests, there is a 14% chance that a rejection will be observed on one of the three tests; for a single control on six different tests, a 26% chance of a rejection on one of the six tests; for a dozen tests, 46%; for twenty tests, 64%. Theoretically, the use of 2 SD control limits is not expected to be cost-effective because of the need to repeat those patient samples from falsely out-of-control runs. Thus there is a disconnect here between the theory and practice in US laboratories today.
One conclusion from the report is that "an opportunity exists to establish an evidence-based approach to QC that can be generalized across institutions." that accounts for the quality required for the intended use of a test, the critical performance characteristics of a measurement procedure (precision, bias), and the critical performance characteristics of a control procedure (probabilities for error detection and false rejection), and the frequency of QC events in high-volume continuous production processes.
Guidance for establishing objective SQC strategies is available from the Clinical Laboratory Standards Institute (CLSI) 2016 edition of its C24-Ed4 document Statistical Quality Control for Quantitative Measurement Procedures.
2 CLSI is a consensus organization that provides recommendations for best practices in medical laboratories. The C24-Ed4 document describes a roadmap for selection of SQC strategies 3 based on the quality required for the test, the precision and bias observed for the measurement procedure, and the risk of patient harm for the SQC procedure (control rules, number of control measurements, frequency of SQC events or run size). This roadmap should certainly fulfill the need for an evidence-based approach for SQC practices.
The C24-Ed4 guidance considers SQC for three different modes of operation: critical control points (CCP), batch processes, and bracketed continuous production processes. CCP SQC might be applied when critical events occur, such as a change in reagent lots, recalibration, and stat testing. Batch SQC involves analysis of a group of patients and controls during the same time period, prior to making a decision about reporting patient results. Bracketed operation applies to continuous production processes where controls are analyzed periodically and the control results from consecutive SQC events are used to decide whether or not to report the patient results between two SQC events. In the survey conducted, 1 SQC practices are described for stat testing, immunochemistry testing, and high production automated analyzers, therefore all three of these modes of operation are observed in the laboratories surveyed.
Traditional SQC design has focused on CCP and batch process applications, employing power curves that represent the rejection characteristics of different control rules and the total number of control measurements (N), 4 critical error graphs that impose the medically important systematic error upon power curves, 5 and charts of operating specifications that show the allowable bias and allowable coefficient of variation (CV) for a defined quality requirement and different SQC procedures. 6 Bracketed operation of continuous production processes requires an additional specification for the frequency of SQC events, or the number of patient samples between SQC events (run size). Parvins patient risk model provides the guidance for optimizing run size.
7 C24-Ed4 recommends the use of bracketed SQC for continuous production analyzers and describes the principles and theory for designing or selecting riskbased SQC strategies that identify control rules, N, and run size.
This guidance for best SQC practices has evidently not yet been adopted by leading academic medical laboratories. We think one reason for this gap between theory and practice is the complexity of the theory and the lack of practical tools to help laboratories apply the evidence-based approach, particularly the assessment of patient risk. However, simpler and more practical tools are now becoming available. Yago 
Materials and Methods
Parvins patient risk model 7 was implemented using the Excel spreadsheets developed by Bayat. 9 Run sizes were determined for the condition where the maximum expected unreliable (or erroneous) final patient test results would be one, that is Parvins MaxE(Nuf) patient risk parameter equals 1.00. That means up to 1 erroneous patient test result may occur due to an undetected error condition in the run sizes that have been determined.
❚Figure 1❚ illustrates the methodology for utilizing a Sigma-Metric Run Size Nomogram together with a Power Function Graph. 11 The top left part of the figure shows the Run Size Nomogram. The top right part shows a Power Function Graph. The table below is used to summarize the critical information. The steps of the planning process are described in the text appearing on the lower left side and those steps are illustrated by the numbers and arrows in the figure.
In short, the Sigma-Metric is calculated from the defined allowable total error (ATE, TEa) for the test and the bias and precision observed for the method (step 1, Sigma value of 5.0). That Sigma value is drawn as a perpendicular line on the Run Size Nomogram (step 2) to identify the run sizes (step 3) for the represented SQC procedures (step 4). Run sizes are tabulated, along with the probabilities for false rejection (P fr ) and error detection (P ed ) obtained from the Power Function Graph (step 5). This information together with the laboratorys maximum workload and desired reporting interval is then used to select appropriate Startup (step 6) and Monitor (step 7) SQC designs, from which SQC schedules can be developed (step 8). Note that the SQC schedule can utilize a CCP design for the initial Startup of a testing process, then employ a different Monitor design in subsequent SQC events based on the desired reporting interval. We refer to this design as multistage SQC. 11 This methodology has been illustrated in detail for an HbA1c test in an earlier publication. 12 It has also been applied for a wide range of Sigma-Metrics and a variety of control rules in order to assess the effects of a wide range of analytical performance in a new planning manual for education and training. 13 Thus it has been demonstrated that the observed Sigma quality for a testing process can be related to critical parameters for the maximum expected run sizes, P fr and P ed for various control rules and the total numbers of control measurements, and also taking into account the maximum workload of the laboratory and its desired reporting interval, ❚Figure 1❚ Methodology for evidence-based statistical quality control (SQC) practices utilizing a Sigma-Metric Run Size Nomogram and a Power Function Graph. In Sigma-Metric Run Size Nomogram, candidate SQC procedures are defined as follows: MR N4 indicates 1 3s /2 2s /R 4s /4 1s with a total number (N) of four control measurements; 1:3s N4 indicates 1 3s with four control measurements; MR N2 is 1 3s /2 2s /R 4s with two control measurements; 1:2s N1 is 1 2s with one control measurement; 1:3s N2 is 1 3s with two control measurements; 1:2.5s N1 is 1 2.5s with one control measurement; 1:3s N1 is 1 3s with one control measurement. In the table and description to provide a selection/design process for evidence-based SQC practices.
Results

Sigma-Metric Run Size Matrix
A summary of critical SQC parameters is shown in ❚Table 1❚. The information from the top seven rows from the table in Figure 1 (candidate SQC procedure, run size, P fr , and P ed ) is included in this matrix for Sigma-Metric value of 5.0; likewise, similar information is provided for Sigma-Metrics of 6.0, 5.5, 4.5, 4.0, and 3.5. The column on the left identifies the control rules, total number of control measurements (N), and P fr (probability for false rejection, shown within the parenthesis). Each row in the table represents a different SQC procedure. For example, MR N4 (0.03) represents a 1 3s /2 2s /R 4s /4 1s multirule procedure with a total of four control measurements per run and a P fr of 0.03 or 3.0%. The columns across show the Sigma quality of testing processes. The intersections of the SQC procedures (rows) and Sigma values (columns) identify the maximum run sizes (1st line) and expected P ed (probability for error detection, second line). For example, the use of an MR N4 multirule procedure with a 5-Sigma process would allow a maximum run size of 1,000 or more patient samples and provide a probability of 1.00 for detecting a medically important systematic error. For comparison, use of MR N=2, such as 1 3s /2 2s / R 4s with a total of two control measurements per run, would permit a maximum run size of 470 patient samples between SQC events.
For and false rejection characteristics for the type of SQC event of interest. 6. Prepare an SQC schedule that identifies the appropriate designs for the SQC events (control rules, N), the sample number for scheduling each QC (based on run size), and the control materials that are to be analyzed.
Westgard Sigma Rules With Run Sizes
A graphical summary of results for a range of SigmaMetrics is provided by the diagram in ❚Figure 2❚. This figure is similar to the traditional diagram of Westgard Rules, but includes a Sigma scale at the bottom. The idea here is to use a methods observed Sigma-Metric to tailor the SQC procedure to the necessary control rules, N, and run size. For example, a testing process having 6-Sigma quality could be controlled using a 1 3s rule with N=2 and would allow a maximum run size of 1,000 patient samples. A 5-Sigma process could be controlled using a 1 3s /2 2s /R 4s multirule procedure with N=2 and a maximum run size of 450. A 4-Sigma process could be controlled with a 1 3s /2 2s / R 4s /4 1s multirule procedure with N=4 and a run size of 200. For a 3-Sigma process, the maximum SQC is needed, which is recommended here to be a 1 3s /2 2s /R 4s /4 1s /6 x multirule with N=6 and a small run size of 45 patient samples. Run sizes in this diagram are approximated from those given in the Matrix and are somewhat more qualitative. Nonetheless, they provide a good starting point for developing evidence-based SQC practices for the bracketed operation of continuous production processes. Note that specific information is not available for P ed and P fr , but the selected control rules and N will provide equal to or greater than 0.90 P ed and equal to or less than 0.05 P fr for recommended processes when the Sigma quality is 6.0, 5.0, and 4.0. Below 4.0, CCP and batch process SQC designs may be better informed by use of the Sigma Run Size Matrix or the traditional SQC design tools.
Discussion
The traditional SQC design process that makes use of Power Function Graphs, Critical-Error Graphs, and Charts of Operating Specifications is still appropriate today for identifying the control rules and total number of control measurements for CCPs and batch processes. For bracketed operation of continuous production processes, an additional parameter is needed for the frequency of SQC events or run size (number of patient samples between consecutive SQC events). Parvins patient risk model provides a quantitative approach for assessing run size, but the theory and calculations are difficult and have limited the applications in medical laboratories. Such applications may be facilitated by simpler tools, such as the Sigma-Metric Run Size Nomogram that was described earlier 11 and the Sigma-Metric Run Size Matrix and the Westgard Sigma Rules with Run Size that are described here.
The estimated run sizes are the maximum numbers of patient samples between bracketed SQC events for the condition that up to 1 erroneous patient test result may occur. Our use of MaxE(Nuf) of 1 is consistent with other applications in the literature. [7] [8] [9] [10] [11] [12] [13] [14] However, laboratories can employ a shorter run size if that is more effective for operations or if the risk is considered to be higher for a particular test and its application. Likewise, tests of lower risk might have longer run sizes, for example double the run size when a MaxE(Nuf) of 2 is desired, triple the run size for MaxE(Nuf) of 3. Along with choice of control rules and N, run size can be adapted for the relative risk of different tests and different medical applications.
The actual run size should not extend across days because the CLIA regulations require controls be analyzed every day, and, for some tests, run sizes should be confined to an 8-hour shift. For bracketed operation of continuous production processes, we recommend a CCP design that provides high error detection at the beginning of operation (Startup SQC design) and a simpler Monitor design that considers the desired reporting interval for the following SQC events. The monitor design can be selected to match the run size with the number of patient results in the desired reporting interval. Three labs in the survey 1 ❚Figure 2❚ Westgard Sigma Rules with Run Sizes for the numbers of patient samples between statistical quality control (SQC) events. Note the Sigma scale at the bottom of the diagram. To apply, determine Sigma-Metric, locate on the Sigma scale, identify control rules, total number of control measurements (N), and frequency of SQC events specified as run size. CV, coefficient of variation; TEa, total error allowable.
reported using some type of multistage SQC, and those designs could also be designed more objectively using available tools.
Applications of these simple tools assume that laboratories define the quality required for the intended use of a test in the form of an allowable total error (ATE, TEa) and document the precision and bias observed for their measurement procedures. These critical parameters are then combined in the calculation of a Sigma-Metric: Sigma=(%ATE |%Bias|)/%CV. The survey of the 21 academic laboratories did not reveal whether quality requirements for intended use had been defined, nor whether the laboratories calculated Sigma-Metrics. These steps should become a priority for laboratories if they want to implement evidence-based SQC practices.
It is expected that evidence-based SQC for high-quality testing processes should lead to more widespread use of 3 SD limits with N=2 and simple multirule procedures such as 1 3s /2 2s /R 4s with N=2, both of which have lower false rejection rates than 2 SD limits. Thats why the current widespread use of 2 SD control limits is so puzzling, particularly since the C24-Ed4 guidance does not include a 1 2s rule in its list of rejection rules. One rational is that the high false rejection rate is reduced by repeating a control because the rejection rule actually becomes 2 2s , which does have a low false rejection rate. However, that practice is supposed to be restricted to only a single repeat 15 to avoid a cascading practice of repeat, repeat, repeat, et al. Given that a repeat will delay the reporting of patient results, we think use of a 1 3 s/2 2s /R 4s multirule makes more sense to confirm a control problem in a single SQC event having 2 control measurements.
Most laboratories in the survey seem to automatically repeat any out-of-range controls. If the repeat control is within range, then patient results are reported. One laboratory also repeats 10 patient samples and another five patient samples to verify consistency of patient results. It is not clear if the repeat control is fresh control material as recommended in C24-Ed4: "Out of control results can be verified by repeating the measurement using fresh QC material in order to rule out any issues that could be caused by compromised QC material Repeating measurement of QC materials should only be used to rule out obvious problems with the QC material itself. Continuing to repeat QC measurements with intention of obtaining in-control results is an unacceptable practice." 2 If fresh control material were used for every repeat, there might be significant additional costs for control materials.
Although it is difficult to rationalize the current use of 2 SD control limits as standard practice, there may be a historical explanation. In the late 1990s, a survey of SQC practices was conducted as part of a College of American Pathologists Q-Probe. 16 The findings from the Q-Probe study included the following: SQC practices were highly variable over the 500 laboratories that participated. SQC was complex because at least 15 different control rules were observed to be in use and approximately 40% of laboratories used more than one control rule. SQC was costly because it consumed from 7% to 10% of samples in routine chemistry applications and up to 37% in an immunoassay application.
The study concluded that laboratory practices needed to be simplified to improve SQC compliance. Twenty years later, we see that the dominant SQC practice is simply compliance with the CLIA requirement to analyze at least two levels of controls. Most US laboratories use only simple 2 SD control limits and are now measuring fewer controls per day, actually as few as two levels once a day in some of these large laboratories.
Recently, Cembrowski and Cervinski 17 also endorsed the need for simple SQC practices, but they pointed to the C24-ED4 guidance together with the Yago and Alcover graphical nomograms 8 for selecting risk-based SQC procedures. The Yago-Alcover nomograms have been expanded by Bayat 9 to include multirule SQC procedures and that work provides the background for our development of the Sigma-Metric Run Size Nomogram, 10, 11 as well as the Sigma-Metric Run Size Matrix and the Westgard Sigma Rules with Run Sizes. Cembrowski and Cervinski 17 conclude that "nomograms plus the elegant CLSI C24 document should help with our comprehension and implementation of more straightforward and intuitive quality control systems."
Our intent, likewise, is to advance and improve SQC practices while at the same time maintaining simplicity in planning evidence-based practices. Doing the right SQC right should be the objective for good laboratory practice. Selection of the right SQC procedure is the first objective. Implementing SQC right will need to consider the informatics capabilities of analytic and computer information systems, which will pose additional problems. Nonetheless, the starting point is selecting the right practices (control rules, number of control measurements, frequency of SQC events or run size), which can now be determined from simple practical tools that are available to medical laboratories.
In conclusion, it should now be practical to adopt the C24-Ed4 2 guidance and roadmap for developing risk-based SQC strategies by utilizing simple tabular and graphical planning tools available in the peer-reviewed literature. An evidence-based approach can be implemented starting with the definition of the quality required for intended use, accounting for the precision and bias observed for the measurement procedure, and considering the rejection characteristics of SQC procedures and their effect on patient risk. Reducing the gap between theory and practice now depends on training and education for laboratory personnel, including the high-level personnel who set the priorities for development and improvement of laboratory services. In these times of lean management with the emphasis on cost control, top management must provide leadership and reassert the importance of better analytical performance and improved SQC practices to assure the safety of our patients. This is also an opportunity for professional organizations to promote excellence rather than settling for compliance. 
